Loading…
Neuphoria Therapeutics Inc. is projected to decline to $3.51 by 2027, a -1% move from its current price of $3.54. NEUP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.39 | $3.54 | $3.70 | -0.01% |
| Jul 14 | $3.33 | $3.54 | $3.76 | -0.01% |
| Jul 15 | $3.29 | $3.54 | $3.81 | -0.02% |
| Jul 16 | $3.25 | $3.54 | $3.86 | -0.02% |
| Jul 17 | $3.22 | $3.54 | $3.90 | -0.03% |
| Jul 18 | $3.19 | $3.54 | $3.93 | -0.04% |
| Jul 19 | $3.16 | $3.54 | $3.96 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.16 | $3.54 | $3.96 | -0.04% |
| Week 2 | $3.01 | $3.54 | $4.15 | -0.08% |
| Week 3 | $2.90 | $3.54 | $4.30 | -0.13% |
| Week 4 | $2.82 | $3.53 | $4.44 | -0.17% |
| Week 5 | $2.74 | $3.53 | $4.55 | -0.21% |
| Week 6 | $2.67 | $3.53 | $4.66 | -0.25% |
| Week 7 | $2.61 | $3.53 | $4.77 | -0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neuphoria Therapeutics Inc. is a clinical stage biopharmaceutical company that discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 receptor for the treatment of social anxiety disorder, and is phase 2b to treat post-traumatic stress disorder.
The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc.
to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.
The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Neuphoria Therapeutics Inc. (NEUP) currently trades at $3.38 with a market capitalization of $18.27M and is ranked 4798 by market cap.
The stock’s near-term outlook is reflected in a year-by-year forecast that shows a neutral stance in 2026, with min $3.38, avg $3.38, max $4.27 and ROI 0. Sentiment for 2026 is NEUTRAL.
Beyond 2026, the forecast turns more bullish: in 2030 the average is $4.66 with a max of $7.86 and ROI of 38%, with a BULLISH sentiment. The long-run view remains highly bullish toward 2050, with an average of $16.37 and a max of $37.65, yielding a 384.4% ROI.
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 51.4% above — a clean break opens room to run.
A major ceiling 71.6% above — clearing it would confirm fresh momentum.
Key NEUP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NEUP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.52 | Buy | $3.57 | Sell |
| MA 10 | $3.79 | Sell | $3.74 | Sell |
| MA 20 | $4.08 | Sell | $4.02 | Sell |
| MA 50 | $4.67 | Sell | $4.40 | Sell |
| MA 100 | $4.60 | Sell | $4.66 | Sell |
| MA 200 | $5.53 | Sell | $5.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.42 | Neutral |
| Stoch RSI (14) | 30.02 | Neutral |
| CCI (20) | -89.31 | Neutral |
| Williams %R (14) | -86.55 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -18.81 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 13.45 | Buy |
| TRIX (15) | -0.89 | Sell |
| Awesome (5,34) | -0.94 | Sell |
| Ultimate (7,14,28) | 23.80 | Buy |
| Momentum (10) | -0.81 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 3.44 | Buy |
| ADX (14) | 27.40 | Sell |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30, indicating modest near-term momentum, while the 50-day simple moving average sits at $4.82 and the 200-day simple moving average is at $5.71.
Support is at $3.38 and resistance at $5.48, framing a 30-day price range of $2.45 to $4.66. The stock’s annualized volatility stands at 90%, highlighting substantial price fluctuation potential within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.38 | $3.54 | $4.43 | 0% | Neutral | |
| $2.64 | $3.51 | $5.00 | -1% | Neutral | |
| $2.31 | $3.21 | $4.82 | -9% | Neutral | |
| $3.00 | $4.34 | $6.80 | +23% | Bullish | |
| $3.42 | $5.12 | $8.30 | +45% | Bullish | |
| $3.41 | $5.28 | $8.83 | +49% | Bullish | |
| $3.64 | $5.81 | $9.97 | +64% | Bullish | |
| $3.02 | $4.97 | $8.74 | +40% | Bullish | |
| $2.95 | $4.98 | $8.95 | +41% | Bullish | |
| $3.67 | $6.39 | $11.71 | +80% | Bullish | |
| $4.11 | $8.12 | $16.19 | +130% | Bullish | |
| $8.37 | $18.61 | $41.73 | +426% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.38 | $3.54 | $4.19 | +0.00% |
| August 2026 | $2.93 | $3.51 | $4.36 | -0.88% |
| September 2026 | $2.90 | $3.52 | $4.45 | +0.34% |
| October 2026 | $2.70 | $3.31 | $4.24 | -6.00% |
| November 2026 | $2.62 | $3.23 | $4.19 | -2.37% |
| December 2026 | $2.72 | $3.38 | $4.43 | +4.52% |
Click any year to see its month-by-month NEUP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Neuphoria Therapeutics Inc.'s 2026 outlook centres on $3.54, within a $3.38 to $4.43 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, NEUP could reach as high as $5.00, with a base case around $3.51 and support toward $2.64 — roughly -1% from $3.54. Price action looks broadly range-bound.
Expect NEUP to range from $2.31 to $4.82 through 2028. The $3.21 average target implies a -9% move from current prices. That is -9% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The NEUP price prediction for 2029 points to an average of $4.34 (low $3.00, high $6.80) — a potential gain of +23% on today's $3.54. Momentum favours further upside here.
In 2030, NEUP is projected to trade between $3.42 and $8.30, averaging $5.12 — a potential gain of +45% from today's $3.54. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Neuphoria Therapeutics Inc.'s 2031 outlook centres on $5.28, within a $3.41 to $8.83 range. That is up +3% on the projected 2030 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2032, NEUP could reach as high as $9.97, with a base case around $5.81 and support toward $3.64 — roughly +64% from $3.54. Buyers look set to stay in control over this stretch.
Expect NEUP to range from $3.02 to $8.74 through 2033. The $4.97 average target implies a +40% move from current prices. That is -14% versus the projected 2032 average. Momentum favours further upside here.
The NEUP price prediction for 2034 points to an average of $4.98 (low $2.95, high $8.95) — a potential gain of +41% on today's $3.54. Buyers look set to stay in control over this stretch.
In 2035, NEUP is projected to trade between $3.67 and $11.71, averaging $6.39 — a potential gain of +80% from today's $3.54. That is up +28% on the projected 2034 average. Momentum favours further upside here.
Neuphoria Therapeutics Inc.'s 2040 outlook centres on $8.12, within a $4.11 to $16.19 range. That is up +27% on the projected 2035 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, NEUP could reach as high as $41.73, with a base case around $18.61 and support toward $8.37 — roughly +426% from $3.54. Momentum favours further upside here.
Investing $1,000 in NEUP today (≈ 282.485876 NEUP) could be worth
$5,257.31
+$4,257.31 (+426%) by 2050 · US Dollar
Based on the average projected NEUP price of $18.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NEUPwould be worth at today's price.
$1,000 invested in NEUP on Jul 10, 2025 (≈ 131.578949 NEUP) would be worth
$465.79
-$534.21 (-53.4%) today · 0.47× · US Dollar
Based on a NEUP entry price of $7.6 vs. today's $3.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.38 | $1,047.34 | +4.7% |
| 1 month ago | $4.42 | $800.9 | -19.9% |
| 3 months ago | $4.78 | $740.59 | -25.9% |
| 6 months ago | $4.2 | $842.86 | -15.7% |
| 1 year ago | $7.6 | $465.79 | -53.4% |
| All time (4.6y) ago | $176.76 | $20.03 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NEUP forecast.
Our base-case forecast reaches $7.10 around 2040.
Implied market cap at $7.10: $38.37M
The multi-year forecast points to a bullish regime emerging in the 2030s. The 2030 average is $4.66 with a max of $7.86 and an ROI of 38%, with a BULLISH sentiment.
The years 2031 and 2032 extend the bullish trajectory, with 2031 average $4.86 (max $8.47, ROI 43.9) and 2032 average $5.30 (max $9.50, ROI 56.7), both labeled BULLISH.
In 2033 the average is $4.29 and the max $7.90 (ROI 27) and in 2034 the average is $4.37 and the max $8.23 (ROI 29.3); 2035 shows a stronger rise to an average of $5.67 and a max of $10.92 (ROI 67.7), all with BULLISH sentiment.
Farther out, 2040 provides an average of $7.07 and a max of $14.89 (ROI 109.3), while 2050 shows an average of $16.37 and a max of $37.65 (ROI 384.4), continuing the bullish stance.
Tap a question to reveal the answer.
In 2030, the forecast shows min $2.98, avg $4.66, max $7.86 with ROI 38% and sentiment BULLISH.
Forecasts show mixed results in early years (2027: ROI -5.2%, 2028: ROI -15.2%), but later years trend bullish (2030–2050) with notable upside (e.g., 2040 ROI 109.3%, 2050 ROI 384.4%). These are estimates, not guarantees.
Yes. The max in 2035 is $10.92, with higher potential in 2040 at $14.89 and in 2050 at $37.65.
RSI14 is 30, with a 30-day range of $2.45 to $4.66. Support is at $3.38 and resistance at $5.48, with volatility at 90%.
Current price is $3.38 and market cap is $18.27M.
Neuphoria Therapeutics Inc. Community Discussion
0Share your Neuphoria Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.